KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vir Biotechnology (VIR) EBT (2018 - 2025)

Vir Biotechnology (VIR) has disclosed EBT for 8 consecutive years, with -$43.1 million as the latest value for Q4 2025.

  • Quarterly EBT rose 58.86% to -$43.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$437.8 million through Dec 2025, up 16.31% year-over-year, with the annual reading at -$437.8 million for FY2025, 16.31% up from the prior year.
  • EBT hit -$43.1 million in Q4 2025 for Vir Biotechnology, up from -$163.0 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $921.9 million in Q1 2022 to a low of -$233.7 million in Q2 2022.
  • Historically, EBT has averaged -$14.2 million across 5 years, with a median of -$120.9 million in 2023.
  • Biggest YoY gain for EBT was 646.43% in 2022; the steepest drop was 477.79% in 2022.
  • Year by year, EBT stood at $545.9 million in 2021, then plummeted by 127.78% to -$151.6 million in 2022, then grew by 20.36% to -$120.8 million in 2023, then increased by 13.32% to -$104.7 million in 2024, then surged by 58.86% to -$43.1 million in 2025.
  • Business Quant data shows EBT for VIR at -$43.1 million in Q4 2025, -$163.0 million in Q3 2025, and -$110.8 million in Q2 2025.